ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million
June 18, 2021Alzamend Neuro, today announced the closing of its initial public offering of 2,500,000 shares of its common stock and full exercise of the underwriter's over-allotment option to purchase 375,000 additional shares of common stock at a price to the public
Pharma Sources Insight January 2025
